Development of a Radiomics-Based Model to Predict Graft Fibrosis in Liver Transplant Recipients: A Pilot Study.

Journal: Transplant international : official journal of the European Society for Organ Transplantation
PMID:

Abstract

Liver Transplantation is complicated by recurrent fibrosis in 40% of recipients. We evaluated the ability of clinical and radiomic features to flag patients at risk of developing future graft fibrosis. CT scans of 254 patients at 3-6 months post-liver transplant were retrospectively analyzed. Volumetric radiomic features were extracted from the portal phase using an Artificial Intelligence-based tool (PyRadiomics). The primary endpoint was clinically significant (≥F2) graft fibrosis. A 10-fold cross-validated LASSO model using clinical and radiomic features was developed. In total, 75 patients (29.5%) developed ≥F2 fibrosis by a median of 19 (4.3-121.8) months. The maximum liver attenuation at the venous phase (a radiomic feature reflecting venous perfusion), primary etiology, donor/recipient age, recurrence of disease, brain-dead donor, tacrolimus use at 3 months, and APRI score at 3 months were predictive of ≥F2 fibrosis. The combination of radiomics and the clinical features increased the AUC to 0.811 from 0.793 for the clinical-only model ( = 0.008) and from 0.664 for the radiomics-only model ( < 0.001) to predict future ≥F2 fibrosis. This pilot study exploring the role of radiomics demonstrates that the addition of radiomic features in a clinical model increased the model's performance. Further studies are required to investigate the generalizability of this experimental tool.

Authors

  • Fakhar Ali Qazi Arisar
    Ajmera Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
  • Emmanuel Salinas-Miranda
    Lunenfeld Tanenbaum Research Institute, Sinai Health System, Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex, Toronto, ON, Canada.
  • Hamideh Ale Ali
    Lunenfeld Tanenbaum Research Institute, Sinai Health System, Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex, Toronto, ON, Canada.
  • Katherine Lajkosz
    Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Catherine Chen
    Ajmera Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
  • Amirhossein Azhie
    Multi Organ Transplant Program, University Health Network, Toronto, ON, Canada.
  • Gerard M Healy
    St Vincent's University Hospital, Dublin, Ireland.
  • Dominik Deniffel
    Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
  • Masoom A Haider
    Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
  • Mamatha Bhat
    Transplant AI Initiative, Ajmera Transplant Program, University Health Network, Toronto, ON, Canada.